With thanks - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

With thanks


Pharmaceutical Technology Europe
Volume 21, Issue 12


Fedra Pavlou
It's the end of the year already and I hope you are looking forward to the festive period and the opportunity to wind down and spend some quality time with family and friends. I'm certainly looking forward to filling my house with too many decorations and having an excuse to over-indulge on good food and wine (I have no excuses during the rest of the year!).

I just wanted to take this opportunity to thank you for a fulfilling and eventful first year as Editor of Pharmaceutical Technology Europe (PTE). The feedback that I have received from readers and industry has proven to me that PTE is indeed a well-regarded and respected publication and I am proud to be a part of it. Thank you to everybody that has taken the time to meet with me at the various meetings that our team has attended this year; it has been a real pleasure. Thank you also to those of you who have joined our LinkedIn ( http://www.pharmtech.com/linkedin) and Twitter ( http://www.pharmtech.com/twitter) groups. It has been incredibly rewarding to see the number of members of our various networking groups growing day-by-day and to see our readers interacting with us and with each other. I also hope that you have enjoyed using our new website, which launched this summer ( http://www.pharmtech.com/). As always, I would welcome any comments that you have to make on our website and our publications, so please do feel free to email me or to post a discussion on our LinkedIn group; your opinions are of the utmost importance to me and to the rest of the PTE team.

I would now like to take this opportunity to wish you happy holidays and to thank you for your continued support of our publication throughout the year. Let's look forward to a happy and successful 2010!

Best wishes,
Fedra Pavlou
Editor-in-Chief

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here